[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100604128":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":31,"responsibleParty":49,"collaborators":19,"id":52,"slug":53,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":19,"eligibilityCriteria":58,"healthyVolunteers":54,"sex":59,"minAge":60,"maxAge":19,"enrollmentInfo":61,"targetDuration":19,"studyType":64,"phases":65,"briefSummary":67,"conditions":68,"keywords":70,"overallStatus":34,"whyStopped":19,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"Beth Israel Deaconess Medical Center","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"photobiomodulation","EXPERIMENTAL","participants will use photobiomodulation daily for 6 months",[13],"Device: photobiomodulation",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DEVICE","a hat with infrared lights will be worn for 30 minutes daily for 6 months",[9],null,[21],{"name":22,"affiliation":5,"role":23},"Daniel Goldenholz, MD PhD","PRINCIPAL_INVESTIGATOR",[25,30],{"name":26,"role":27,"phone":28,"phoneExt":19,"email":29},"Daniel Goldenholz, MD, PhD","CONTACT","617-632-8930","daniel.goldenholz@bidmc.harvard.edu",{"name":22,"role":27,"phone":28,"phoneExt":19,"email":29},[32],{"facility":33,"status":34,"city":35,"state":36,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"BIDMC","RECRUITING","Boston","Massachusetts","02215","United States","US",{"type":41,"coordinates":42},"Point",[43,44],-71.05977,42.35843,{"lat":44,"lon":43},[47,48],{"name":22,"role":27,"phone":28,"phoneExt":19,"email":29},{"name":22,"role":23,"phone":19,"phoneExt":19,"email":19},{"type":23,"investigatorFullName":50,"investigatorTitle":51,"investigatorAffiliation":5,"oldNameTitle":19,"oldOrganization":19},"Daniel Goldenholz","Assistant Professor","100604128","infrared-photobiomodulation-in-humans-with-epilepsy-100604128",false,"NCT07145489","Infrared Photobiomodulation in Humans With Epilepsy","An Open Label Pilot Study of Infrared Photobiomodulation in Humans With Epilepsy","Inclusion Criteria:\n\n* Drug resistant epilepsy\n* Age 18 or older\n* Average seizure rate of at least 2 seizures per month\n* Accurate seizure diary with at least 3 months recorded\n\nExclusion Criteria:\n\n* Implanted intracranial neurostimulation device (DBS or RNS)\n* Intracranial shunt\n* Skin photosensitivity\n* Cancer on scalp\n* Taking any medication that can cause photosensitivity","ALL","18 Years",{"count":62,"type":63},13,"ESTIMATED","INTERVENTIONAL",[66],"NA","Drug-resistant epilepsy represents roughly 40% of people with epilepsy. It is very challenging to stop seizures in this condition, and the treatment options are limited. This study aims to investigate a new treatment that involves using infra-red light. In animals, this treatment has shown promise as a possible way to reduce seizures, but it has not been tested in humans for this. The investigators are interested to know if it can reduce seizures, and how comfortable it is to be treated with this therapy.",[69],"Drug Resistant Epilepsy",[71,9,72],"epilepsy","seizure","2026-02-03",{"date":75,"type":76},"2026-02-04","ACTUAL",{"date":78,"type":76},"2025-11-25",{"date":80,"type":63},"2027-09-25",{"name":5,"class":6},1]